We examined clinical outcomes in a population-based cohort of EGFR mutant advanced NSCLC patients, exploring the potential role of factors including tumour EGFR mutation fraction and cellularity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback